BIll Goolsbee was the CEO of SAREPTA...why would he chair this project if he didn't think Atl 1102 had a big chance ...
"In Sep 2016, Sarepta gained accelerated approval for Exondys 51 in the U.S. for the treatment of patients suffering from DMD amenable to exon 51 skipping. Exondys 51 is the first approved disease-modifying therapy for DMD in the U.S. as well as the company's first product to receive marketing approval. The FDA approval of Exondys 51 was thus a huge boost for Sarepta as DMD is a devastating and incurable muscle-wasting disease. There is a significant unmet need for DMD treatments. Exondys 51 has the potential to address up to 13% of the total DMD population. In the U.S., Sarepta commenced shipments of Exondys 51 at the end of the third quarter of 2016. Also, a marketing application is under review in the EU, which if approved, should augment sales....
ANP could be a takeover target by SAREPTA...$$$
- Forums
- ASX - By Stock
- News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review
BIll Goolsbee was the CEO of SAREPTA...why would he chair this...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M |
Open | High | Low | Value | Volume |
10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 319942 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 86442 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 319942 | 0.100 |
3 | 113179 | 0.099 |
1 | 13000 | 0.098 |
2 | 130927 | 0.097 |
1 | 10004 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 86442 | 3 |
0.110 | 290000 | 4 |
0.115 | 601850 | 5 |
0.120 | 275642 | 8 |
0.125 | 65000 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |